This week, members of the Parkinson’s community are gathering for the 3rd World Parkinson Congress in Montreal, Canada. Can’t make it to Montreal? PDF is bringing the WPC to you.
We’ll be reporting straight from Montreal, providing scientific updates, interviews with delegates, photos of the Parkinson’s Quilt display and more.
What do you want to know from the meeting? Give us some ideas of the topics you’d like covered.
We’ll do our best to report back with help from our on-the-ground reporters, members of our People With Parkinson’s Advisory Council and more than 50 of our Research Advocates (check out their bios here).
From Linda Morgan, M.B.A., R.Ph., member People with Parkinson’s Advisory Council
I arrived early in Montreal for the 3rd World Parkinson Congress, which will officially start on Tuesday.
I came in early to be part of an ‘historic’ dinner and meeting between researchers from the Parkinson Study Group (PSG) and those of us involved with Parkinson’s Advocates in Research (PAIR).
This Thursday will be a very special day for the Parkinson’s community: the debut of The Michael J. Fox show, a new TV comedy series starring the eponymous TV newscaster who lives with Parkinson’s disease. Michael has done so much to help this community — through the foundation he created, of course, but also by simply giving a “face” to Parkinson’s around the world. It is no exaggeration to say that he has transformed the way we look at PD and the people who live with it, and the level of urgency we all feel to bring resources to bear on ending it once and for all.
From James Beck, Ph.D., Vice President of Research Programs
Using old drugs as new cures seems like a surefire winner. It may be. However, after attending a recent meeting outside London hosted by the Cure Parkinson’s Trust, a small yet impactful British charity, it is clear that this path is neither clear nor easy. A committee of experts at the meeting evaluated and prioritized dozens of existing compounds – many are drugs used to treat other diseases – based upon their potential to stop Parkinson’s disease.
From James Beck, Ph.D., Director of Research Programs
This blog is part two in a series of three about the BigBrain.
Several weeks ago saw the announcement of a description of a new and highly detailed atlas of the brain, called BigBrain. PDF wrote about how one person, making the decision to donate their brain, has made a significant contribution to science. Indeed, that is true. But what does this really mean for the future of neuroscience … and Parkinson’s research?
When opening the Sunday Review section of the New York Times this past weekend, I did a double-take as a topic of much discussion here at PDF was featured front and center – trumping commentary on the state of the economy, international relations and the latest political debate.
“Do Clinical Trials Work?,” by Clifton Leaf serves as a primer on some of the key issues that prevail within the clinical research enterprise – the tension between scientific inquiry and patient priorities; the odds that study sponsors take when betting on the success of a potential therapy; and the disconnect between those who participate in a study and those who may actually benefit from the treatment being tested. It also serves as yet another wake-up call on why people who are living with a disease, be it cancer, Alzheimer’s or Parkinson’s, need to be formally included in research decision-making.